Propylallyltryptamine

Last updated
Propylallyltryptamine
Propylallyltryptamine.svg
PALT 3D.png
Clinical data
Other namesPALT; N-Propyl-N-allyltryptamine; ASR-3004; ASR3004
Drug class Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • N-[2-(1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-1-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C16H22N2
Molar mass 242.366 g·mol−1
3D model (JSmol)
  • CCCN(CCC1=CNC2=CC=CC=C21)CC=C
  • InChI=1S/C16H22N2/c1-3-10-18(11-4-2)12-9-14-13-17-16-8-6-5-7-15(14)16/h3,5-8,13,17H,1,4,9-12H2,2H3
  • Key:BPHDZENPKNMIRD-UHFFFAOYSA-N

Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family. [1] It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT). [1] The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor. [1] It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). [1] The chemical synthesis of PALT has been described. [1] A notable analogue of PALT is iPALT (ASR-3003). [1] PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024. [1]

See also

References

  1. 1 2 3 4 5 6 7 US 20240277665A1,Daley PF, Cozzi NV, Callaway WB,"Asymmetric allyl tryptamines",issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.